Open Access Article
International Journal of Clinical Research. 2023; 7: (4) ; 151-154 ; DOI: 10.12208/j.ijcr.20230193.
Efficacy of recombinant human erythropoietin on anemia in patients undergoing lung cancer chemotherapy
重组人促红细胞生成素对肺癌化疗患者贫血的疗效观察
作者:
熊伟 *
赤壁市蒲纺医院肿瘤科 湖北咸宁
*通讯作者:
熊伟,单位:赤壁市蒲纺医院肿瘤科 湖北咸宁;
发布时间: 2023-04-13 总浏览量: 345
PDF 全文下载
引用本文
摘要
目的 分析肺癌化疗患者的贫血的原因,探讨重组人促红细胞生成素应用于肺癌化疗患者后疗效及不良反应。方法 采用我院HIS系统收集我院2020年5月—2022年4月两年间,通过临床和病理确诊为肺癌患者并且接受化疗的40例患者,年龄在40岁—75之间,分为二组,实验组(N=20)和对照组(N=20),均接受3个周期化疗,化疗期间出现贫血均给予铁剂治疗。实验组在每个化疗周期结束后5小时在给予铁剂治疗的基础上给予皮下注射重组人促红细胞生成素10000IU,每周注射三次,连续注射4周。对比分析两组患者的治疗效果。结果 注射重组人促红细胞生成素患者血红蛋白、红细胞、红细胞比容三项指标改善明显优于未注射组(P<0.05)。在注射重组人促红细胞生成素4周内,随着治疗时间的延长,贫血改变越明显。结论 重组人促红细胞生成素治疗化疗期间出现的贫血有一定疗效,同时需注意用药时的不良反应,及时进行监测处理。
关键词: 肺癌;化疗;贫血;促红细胞生成素
Abstract
Objective: To analyze the causes of anemia in lung cancer chemotherapy patients and explore the efficacy and adverse reactions of recombinant human erythropoietin applied to lung cancer chemotherapy patients. Method: Our hospital's HIS system was used to collect 40 lung cancer patients who were clinically and pathologically diagnosed with lung cancer and underwent chemotherapy from May 2020 to April 2022, aged between 40 and 75 years old. They were divided into two groups: the experimental group (N=20) and the control group (N=20), both receiving three cycles of chemotherapy. Anemia during the chemotherapy period was treated with iron. The experimental group received subcutaneous injection of 10000 IU of recombinant human erythropoietin 5 hours after the end of each chemotherapy cycle, in addition to iron therapy, three times a week for 4 consecutive weeks. The treatment effects of the two groups of patients were compared and analyzed. Results The improvement of hemoglobin, red blood cell and hematocrit in patients injected with recombinant human erythropoietin was significantly better than that in patients without injection(P<0.05). Within 4 weeks of injection of recombinant human erythropoietin, the anemia changes become more pronounced with the prolongation of treatment time. Conclusion : Recombinant human erythropoietin has a certain therapeutic effect on anemia during chemotherapy, and attention should be paid to adverse reactions during medication, and timely monitoring and treatment should be carried out.
Key words: Lung cancer, chemotherapy, anemia, erythropoietin
参考文献 References
[1] 吴付兵,王星,王康霞,等.促红细胞生成素对胃癌相关性贫血患者的疗效[J]现代肿瘤医学,2015,23(2);241-243.
[2] 刘鹏辉,廖国清,王红梅,等.促红细胞生成素治疗非小细胞肺癌化疗所致贫血的临床研究 [J]. 新乡医学院学报,2006,23(4):364-366.
[3] 陈文俊,原少斐,孙洪雨,等.促红细胞生成素联合健脾补肾益气养血方治疗化疗相关性贫血的疗效观察[J].中国全科医学,2010,13(5):552-554,566.
[4] 李博, 石远凯. 贫血对肿瘤患者的影响及治疗[J].癌症进展, 2007,5(3): 269-275.
[5] 姜永生,王芙蓉.452例恶性肿瘤患者贫血状况及影响因素分析[J].中国医院药学杂志,2012,32(20):1685-1687.
[6] 祁亚平,马洪涛.促红细胞生成素治疗中重度新生儿缺氧缺血性脑病的临床疗效观察[J].中国医药指南,2013,11(11) : 590 - 591.
[7] 傅海霞,关广聚.促红细胞生成素诱发高血压机制研究进展[J].山东医药,2003,43(22) : 63.
[8] 杨元勋,钱正刚,李刚.109例重组人促红细胞生成素药物不良反应文献分析[J].药学服务与研究2014.2(14); 45-47.
引用本文
熊伟, 重组人促红细胞生成素对肺癌化疗患者贫血的疗效观察[J]. 国际临床研究杂志, 2023; 7: (4) : 151-154.